Repurposing Opportunity Engine

Drugs whose realized polypharmacology hits a kinase other than their primary labeled target. Sorted by inhibition × selectivity — high inhibition on a secondary kinase combined with overall drug selectivity (Gini) implies a real repurposing signal, not non-specific promiscuity.

100 opportunities (top 100)

#	Drug	Primary target	Secondary target hit	Inhibition	Gini	Score
1	Zanubrutinib	BTK	ERBB4_HER4	99.6%	0.788	78.47
2	Zanubrutinib	BTK	BMX_ETK	99.3%	0.788	78.18
3	Zanubrutinib	BTK	BLK	99.1%	0.788	78.06
4	Sorafenib	FLT1_VEGFR1	RAF1	100.0%	0.776	77.61
5	Sorafenib	FLT1_VEGFR1	ARAF	100.0%	0.776	77.60
6	Sorafenib	FLT1_VEGFR1	BRAF	98.5%	0.776	76.48
7	Sorafenib	FLT1_VEGFR1	HIPK4	98.5%	0.776	76.46
8	Zanubrutinib	BTK	TXK	96.9%	0.788	76.32
9	Nilotinib	BCR_ABL	DDR2	99.7%	0.765	76.26
10	Sorafenib	FLT1_VEGFR1	C_KIT	98.2%	0.776	76.24
11	Sorafenib	FLT1_VEGFR1	FMS	98.1%	0.776	76.14
12	Mobocertinib	EGFR	ERBB2_HER2	99.8%	0.757	75.62
13	Nilotinib	BCR_ABL	EPHB1	98.8%	0.765	75.61
14	Sorafenib	FLT1_VEGFR1	FLT3	97.3%	0.776	75.55
15	Nilotinib	BCR_ABL	EPHB2	98.7%	0.765	75.51
16	Mobocertinib	EGFR	BLK	99.7%	0.757	75.50
17	Mobocertinib	EGFR	ERBB4_HER4	99.6%	0.757	75.45
18	Zanubrutinib	BTK	TEC	95.8%	0.788	75.43
19	Nilotinib	BCR_ABL	DDR1	98.5%	0.765	75.41
20	Encorafenib	BRAF	RAF1	99.7%	0.755	75.28
21	Nilotinib	BCR_ABL	RAF1	98.3%	0.765	75.19
22	Cabozantinib	RET	DDR2	100.0%	0.751	75.07
23	Cabozantinib	RET	TRKB	100.0%	0.751	75.07
24	Cabozantinib	RET	DDR1	100.0%	0.751	75.07
25	Cabozantinib	RET	HIPK4	100.0%	0.751	75.07
26	Nilotinib	BCR_ABL	ABL1	98.0%	0.765	74.96
27	Nilotinib	BCR_ABL	PDGFRA	97.9%	0.765	74.95
28	Sorafenib	FLT1_VEGFR1	DDR2	96.3%	0.776	74.72
29	Nilotinib	BCR_ABL	EPHA2	97.6%	0.765	74.71
30	Sorafenib	FLT1_VEGFR1	YSK4_MAP3K19	96.3%	0.776	74.70
31	Cabozantinib	RET	BRK	99.5%	0.751	74.69
32	Cabozantinib	RET	C_MET	99.2%	0.751	74.48
33	Mobocertinib	EGFR	BMX_ETK	98.1%	0.757	74.33
34	Sorafenib	FLT1_VEGFR1	PDGFRA	95.6%	0.776	74.18
35	Nilotinib	BCR_ABL	ABL2_ARG	96.9%	0.765	74.15
36	Mobocertinib	EGFR	BTK	97.4%	0.757	73.75
37	Mobocertinib	EGFR	ACK1	97.4%	0.757	73.75
38	Encorafenib	BRAF	IRAK1	97.5%	0.755	73.67
39	Mobocertinib	EGFR	JAK3	97.2%	0.757	73.66
40	Encorafenib	BRAF	ARAF	97.4%	0.755	73.58
41	Mobocertinib	EGFR	TXK	97.1%	0.757	73.58
42	Zanubrutinib	BTK	BRK	93.4%	0.788	73.56
43	Osimertinib	EGFR	ERBB4_HER4	100.0%	0.733	73.34
44	Cabozantinib	RET	LCK	97.5%	0.751	73.17
45	Sorafenib	FLT1_VEGFR1	DDR1	94.2%	0.776	73.08
46	Erdafitinib	FGFR1	FGFR3	99.1%	0.737	73.01
47	Erdafitinib	FGFR1	FGFR2	99.0%	0.737	72.94
48	Sorafenib	FLT1_VEGFR1	RET	94.0%	0.776	72.92
49	Osimertinib	EGFR	ERBB2_HER2	99.4%	0.733	72.87
50	Cabozantinib	RET	C_MER	97.0%	0.751	72.80
51	Nilotinib	BCR_ABL	LCK	95.1%	0.765	72.80
52	Cabozantinib	RET	YSK4_MAP3K19	96.8%	0.751	72.66
53	Nilotinib	BCR_ABL	EPHB4	94.6%	0.765	72.38
54	Ibrutinib	BTK	ERBB4_HER4	100.0%	0.723	72.25
55	Nilotinib	BCR_ABL	EPHA4	94.4%	0.765	72.25
56	Erdafitinib	FGFR1	FGFR4	98.0%	0.737	72.23
57	Erdafitinib	FGFR1	C_KIT	98.0%	0.737	72.23
58	Ibrutinib	BTK	TXK	99.9%	0.723	72.20
59	Erdafitinib	FGFR1	FLT4_VEGFR3	97.9%	0.737	72.14
60	Erdafitinib	FGFR1	LYN	97.8%	0.737	72.08
61	Ibrutinib	BTK	BLK	99.7%	0.723	72.07
62	Cabozantinib	RET	ROS_ROS1	96.0%	0.751	72.04
63	Cabozantinib	RET	AXL	95.9%	0.751	71.99
64	Erdafitinib	FGFR1	FMS	97.6%	0.737	71.89
65	Darovasertib	PKCA	PKCD	99.9%	0.719	71.87
66	Regorafenib	FLT1_VEGFR1	RAF1	99.9%	0.719	71.86
67	Darovasertib	PKCA	PKCTHETA	99.9%	0.719	71.86
68	Ribociclib	CDK4_CYCLIN_D1	CDK4_CYCLIN_D3	98.6%	0.729	71.86
69	Cabozantinib	RET	EPHA6	95.7%	0.751	71.84
70	Darovasertib	PKCA	PKCEPSILON	99.8%	0.719	71.81
71	Nilotinib	BCR_ABL	EPHA5	93.8%	0.765	71.80
72	Darovasertib	PKCA	PKCETA	99.8%	0.719	71.80
73	Lenvatinib	FLT1_VEGFR1	RET	98.8%	0.726	71.79
74	Vandetanib	KDR_VEGFR2	EGFR	99.3%	0.723	71.78
75	Ibrutinib	BTK	EGFR	99.3%	0.723	71.77
76	Ibrutinib	BTK	CSK	99.3%	0.723	71.73
77	Quizartinib	FLT3	C_KIT	97.3%	0.737	71.73
78	Alpelisib	PI3K	RET	99.6%	0.720	71.71
79	Pemigatinib	FGFR2	FGFR1	99.9%	0.718	71.67
80	Darovasertib	PKCA	PKCB2	99.5%	0.719	71.61
81	Osimertinib	EGFR	TXK	97.6%	0.733	71.61
82	Ibrutinib	BTK	FGR	99.1%	0.723	71.59
83	Osimertinib	EGFR	JAK3	97.5%	0.733	71.54
84	Mobocertinib	EGFR	ITK	94.4%	0.757	71.54
85	Vandetanib	KDR_VEGFR2	LCK	98.9%	0.723	71.49
86	Cabozantinib	RET	FLT4_VEGFR3	95.2%	0.751	71.46
87	Alpelisib	PI3K	TRKB	99.3%	0.720	71.46
88	Ibrutinib	BTK	BMX_ETK	98.9%	0.723	71.46
89	Erdafitinib	FGFR1	EIF2AK2	97.0%	0.737	71.43
90	Alpelisib	PI3K	TRKC	99.3%	0.720	71.43
91	Sorafenib	FLT1_VEGFR1	MUSK	92.0%	0.776	71.43
92	Ibrutinib	BTK	ERBB2_HER2	98.8%	0.723	71.38
93	Cabozantinib	RET	KDR_VEGFR2	95.0%	0.751	71.35
94	Ibrutinib	BTK	TEC	98.7%	0.723	71.34
95	Cabozantinib	RET	FLT3	95.0%	0.751	71.32
96	Osimertinib	EGFR	ROS_ROS1	97.2%	0.733	71.31
97	Pemigatinib	FGFR2	FGFR3	99.4%	0.718	71.29
98	Ibrutinib	BTK	JAK3	98.6%	0.723	71.26
99	Darovasertib	PKCA	PKCB1	99.0%	0.719	71.24
100	Vandetanib	KDR_VEGFR2	RET	98.6%	0.723	71.24

Provenance · saifudeen2026@1.0.0 · API 0.1.0 · latency 3.7 ms · rendered 2026-05-21T12:05:53.099Z · query GET /api/v1/repurposing